title: Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease.
abstract: Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation coupled with an abnormal inflammatory process. It is associated with high morbidity and mortality. Leukotriene modifiers, approved by the United States Food and Drug Administration as treatment for asthma and allergic rhinitis, may also alleviate the abnormal inflammatory response seen in patients with COPD. To explore the outcomes of research in this area, we conducted a literature search from 1950-2007, using the PubMed database. We found no published studies that provided conclusive evidence that the available leukotriene modifiers benefit patients with COPD. However, data do suggest that leukotriene modifiers may offer benefits to patients with COPD, including effects that pertain to airflow limitation, neutrophil and lymphocyte chemotaxis, and neutrophil longevity. Added to conventional treatment, these agents appear to reduce symptoms, improve objective measures of disease, and control inflammation. Further studies are needed to determine the precise role of leukotriene modifiers in the treatment of COPD.
authors.affiliation: Department of Pharmacy, Methodist University Hospital, Memphis, Tennessee 38104, USA.
authors.forename: Justin B
authors.initials: JB
authors.lastname: Usery
authors.forename: Timothy H
authors.initials: TH
authors.lastname: Self
authors.forename: Muthiah P
authors.initials: MP
authors.lastname: Muthiah
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Finch